Herceptin Biosimilar Market
Herceptin® sales peaked in 2018, a year before the primary patent covering the drug expired in the US; in order to carve out a share of the associated ...
R A
Roots Analysis has announced the addition of the “Herceptin® (Trastuzumab) Biosimilars ” report to its list of offerings. The first trastuzumab ...